Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
Jaehong Kim, Shanshan Wang, Slaven Sikirica, View ORCID ProfileJason Shafrin
doi: https://doi.org/10.1101/2023.12.05.23299552
Jaehong Kim
1FTI Consulting, Center for Healthcare Economics and Policy, Washington, D.C
PhDShanshan Wang
1FTI Consulting, Center for Healthcare Economics and Policy, Washington, D.C
MPHSlaven Sikirica
2Lexicon Pharmaceuticals, The Woodlands, Texas
MBA, MScJason Shafrin
1FTI Consulting, Center for Healthcare Economics and Policy, Washington, D.C
PhDData Availability
The data that support the findings of this study are available are publicly available and can be found within the references of the manuscript.
Posted December 06, 2023.
Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
Jaehong Kim, Shanshan Wang, Slaven Sikirica, Jason Shafrin
medRxiv 2023.12.05.23299552; doi: https://doi.org/10.1101/2023.12.05.23299552
Subject Area
Subject Areas
- Addiction Medicine (403)
- Allergy and Immunology (712)
- Anesthesia (205)
- Cardiovascular Medicine (2966)
- Dermatology (251)
- Emergency Medicine (445)
- Epidemiology (12794)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4614)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2940)
- Health Policy (1072)
- Hematology (393)
- HIV/AIDS (930)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (474)
- Neurology (4396)
- Nursing (237)
- Nutrition (646)
- Oncology (2287)
- Ophthalmology (651)
- Orthopedics (259)
- Otolaryngology (327)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (502)
- Public and Global Health (6987)
- Radiology and Imaging (1541)
- Respiratory Medicine (918)
- Rheumatology (443)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)